Momenta Pharmaceuticals, Inc.

Massachusetts Institute of Technology

Janssen Biotech, Inc.

Evolved by Nature, Inc.

Carlos J Bosques

Jonathan C Lansing

Ian Christopher Parsons

Nathaniel J Washburn

James Meador, Iii

Brian Edward Collins

Daniel Ortiz

Dorota A Bulik

Ram Sasisekharan

Leona E Ling

Rahul Raman

Laura Rutitzky

Ishan Capila

Nur Sibel Gunay

Kevin Pojasek

Ting Zheng

Vikas Prabhakar

James S Huston

Ganesh Kaundinya

Naveen Bhatnagar

Cuihua Liu

Anthony Manning

Jennifer Murphy

Lakshmanan Thiruneelakantapillai

Jay Duffner

Thomas E Prod'Homme

Zachary Shriver

Gregory H Altman

Daniela Beccati

Xiangping Zhu

Nishla Keiser

Xiao-Jin Xu

Aravind Srinivasan

Pankaj Gandhe

Sasi Raguram

Enrique Arevalo

Scott Bailey

Kevin Millea

Hetal Sarvaiya

Sathya Prabbhakar

Lynn Markowitz

Julia Brown

Sean Smith

Maurice Gaston Hains

Karthik Viswanathan

Ganesh Venkataraman

James R Myette

Enrico Mortarino

Rebecca L Lacouture

Rajeev Chillakuru

Birgit Corinna Schultes

John Robblee

Maria L Ufret

Peng Xu

Daniela Becatti

Patrik Johansson

Patrick Yacono

Erlei Jin

Brian E Collins

Sibel Nur Gunay

James Iii Meador

Nathanial J Washburn

Brigit C Schultes

Thomas E PROD'HOMME

Jennifer Lynn Murphy

Zachary Schriver

The present invention relates to methods of using biologically active Fc domain-containing therapeutic constructs (Fc constructs) to induce immune cell activation of the immune response in a subject, and for example, to treat diseases such as cancers and infections in a subject. Such Fc constructs may include 5 or more Fc domains.

Methods related to engineered Fc constructs

The present disclosure relates to engineered IgG Fc constructs and uses thereof.

Compositions and methods related to engineered Fc constructs

The invention encompasses the discovery that Fc-containing polypeptides that include branched glycans and that are sialylated on the branched glycan (e.g., on an α 1,3 and/or α 1,6 arm in the Fc region's N-linked glycosylation site), with, e.g., a NeuAc-α 2,6-Gal or NeuAc-α 2,3-Gal terminal linkage, are useful in treating neurodegeneration, e.g., in the treatment of neurodegenerative diseases such as Alzheimer's Disease. The present disclosure provides, in part, methods for treating neurodegeneration or neurodegenerative diseases by administering compositions containing such Fc-containing polypeptides as well as methods for evaluating, identifying, and/or producing (e.g., manufacturing) such polypeptides for the treatment of neurodegeneration.

Methods for the treatment of neurodegeneration

Hyaluronic acid and silk fibroin or silk fibroin fragments tissue fillers and methods of making and using the same are provided herein. In some embodiments, the disclosure relates to a biocompatible tissue filler comprising silk fibroin or silk fibroin fragments, hyaluronic acid (HA), and polyethylene glycol (PEG) and/or polypropylene glycol (PPG), wherein a portion of the HA is modified or crosslinked by one or more linker moieties comprising one or more of polyethylene glycol (PEG), polypropylene glycol (PPG), and a secondary alcohol, wherein the linker moieties are attached to the HA at one end of the linker.

Silk-hyaluronic acid tissue fillers and methods of making and using the same

The present invention relates to compositions and methods of engineered IgG Fc constructs, wherein said Fc constructs include one or more Fc domains.

Silk processed, coated, repaired, and/or infused faux or bonded leather, or faux or bonded leather articles, and methods of preparing the same are disclosed herein.

Silk protein bonded layered materials and methods of making and using thereof

Engineered Fc constructs

The present disclosure relates to compositions and methods of engineered IgG Fc constructs, wherein the Fc constructs include one or more Fc domains.

The invention encompasses the discovery that Fc-containing polypeptides that include branched glycans and that are sialylated on the branched glycan (e.g., on an &#x3b1; 1,3 and/or &#x3b1; 1,6 arm in the Fc region's N-linked glycosylation site), with, e.g., a NeuA-&#x3b1; 2,6-Gal or NeuAc-&#x3b1; 2,3-Gal terminal linkage, are useful in treating neurodegeneration, e.g., in the treatment of neurodegenerative diseases such as Alzheimer's Disease. The present disclosure provides, in pert, methods for treating neurodegeneration or neurodegenerative diseases by administering compositions containing such Fc-containing polypeptides as well as methods for evaluating, identifying, and/or producing (e.g., manufacturing) such polypeptides for the treatment of neurodegeneration.

The present invention relates to engineered IgG Fc constructs and uses thereof.

The invention encompasses the discovery that Fc-containing polypeptides that include branched glycans and that are sialylated on the branched glycan (e.g., on an &#x3b1; 1,3 and/or &#x3b1; 1,6 arm in the Fc region's N-linked glycosylation site), with, e.g., a NeuAc-&#x3b1; 2,6-Gal or NeuAc-&#x3b1; 2,3-Gal terminal linkage, are useful in treating neurodegeneration, e.g., in the treatment of neurodegenerative diseases such as Alzheimer's Disease. The present disclosure provides, in part, methods for treating neurodegeneration or neurodegenerative diseases by administering compositions containing such Fc-containing polypeptides as well as methods for evaluating, identifying, and/or producing (e.g., manufacturing) such polypeptides for the treatment of neurodegeneration.

Sulfated glycoproteins, and methods of making and using such sulfated glycoproteins, are described.

Modified glycoproteins

Modified glycoproteins, and methods of making and using such modified glycoproteins, are described.

Growing community of inventors

Arlington, MA, United States of America

Carlos J Bosques